NCATS-SM0225

Overview

NCATS-SM0225 is an endoplasmic reticulum-associated degradation ( ERAD ) inhibitor and a direct binder of VDAC1 , VDAC2 and VDAC3 . NCATS-SM0225 exhibits an IC 50 of 1.02 μM for ERAD and a K d of 3.13 μM for human VDAC1 binding. NCATS-SM0225 disrupts cellular calcium homeostasis, enhances VDAC1-IP3R coupling and activating PERK . NCATS-SM0225 selectively kills cancer cells, exhibits tumor growth inhibitory effects in melanoma xenograft models. NCATS-SM0225 can be used for research on multiple cancers including melanoma, as well as the molecular mechanisms of ERAD and calcium homeostasis regulation.

Application

Products | Products > Disease Areas > Digestive System Cancer | Products > Disease Areas > Pancreatic Cancer | Products > Disease Areas > Melanoma | Products > Disease Areas > Glioma | Products > Disease Areas > Cancer | Products > Disease Areas > Digestive System Disease | Products > Disease Areas > Breast Cancer | Products > Disease Areas > Liver Cancer | Products > Signaling Pathways > Membrane Transporter/Ion Channel | Products > Signaling Pathways > Cell Cycle/DNA Damage | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > VDAC | Products > Signaling Pathways > PERK

Product Information

• Catalog No.: HY-181529
• CAS No.: 1212623-02-3
• Molecular Formula: C23H28N2O4S2
• Molecular Weight: 460.61
• Purity: 99.98%
• Storage: Please store the product under the recommended conditions in the Certificate of Analysis.

Source

Original product source